Actemra Drug Market Insights
The market for Actemra (tocilizumab) is substantial, driven by its use in treating various inflammatory conditions. Its market presence is influenced by patent expirations, ongoing litigation, and the development of biosimilars.
When does Actemra's patent expire?
Actemra's primary patents are set to expire in the coming years. For example, U.S. Patent No. 8,663,688, which covers certain methods of using tocilizumab, is scheduled to expire on October 15, 2027 [1]. Other related patents may have different expiration dates, impacting the exclusivity period for the drug. Information on patent expirations for many drugs, including Actemra, can be found on DrugPatentWatch.com [2].
What are the approved uses for Actemra?
Actemra is approved for treating several conditions, including moderate to severe active rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs) [3]. It is also indicated for active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older [3]. Additionally, Actemra is used for active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older [3]. During the COVID-19 pandemic, it received emergency use authorization and later full FDA approval for treating hospitalized patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive, or invasive mechanical ventilation [3][4].
How does Actemra work?
Actemra is a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody [3]. IL-6 is a cytokine that plays a significant role in inflammation and immune system responses. By binding to both soluble and membrane-bound IL-6 receptors, Actemra blocks IL-6 signaling, thereby reducing inflammation associated with certain autoimmune diseases [3].
Who are Actemra's competitors?
The market for autoimmune disease treatments is competitive, with several other drugs targeting similar inflammatory pathways. Competitors include other IL-6 inhibitors, as well as drugs that target different mechanisms like TNF-alpha inhibitors (e.g., adalimumab, etanercept), JAK inhibitors (e.g., baricitinib, tofacitinib), and IL-1 inhibitors [5]. The introduction of biosimilars to Actemra will also increase competition.
What is the status of Actemra biosimilars?
The development and approval of biosimilars for Actemra are underway. Companies are seeking to bring biosimilar versions to market, which are expected to offer lower-cost alternatives once patents expire and regulatory approvals are granted. For instance, Samsung Bioepis and Biogen have developed a biosimilar candidate, and discussions and legal challenges surrounding biosimilar entry are common in this space [6].
What are the risks associated with Actemra?
Actemra carries a boxed warning for serious infections, including tuberculosis and invasive fungal infections, and it may mask signs of infection [3]. Other serious risks include an increased risk of tears or holes in the stomach or intestines (gastrointestinal perforation), and potential risks to the liver [3]. Patients may also experience changes in cholesterol levels, decreased neutrophil counts, and elevations in liver enzymes [3].
What is the clinical data supporting Actemra?
Clinical trials have demonstrated the efficacy of Actemra in managing rheumatoid arthritis, PJIA, and SJIA, showing significant improvements in disease activity and reduction in inflammation [3]. Data also supports its use in hospitalized COVID-19 patients, demonstrating improved clinical outcomes [4].
---
Sources:
[1] U.S. Patent No. 8,663,688. (n.d.). Retrieved from https://patents.google.com/patent/US8663688B2/en
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] Actemra Prescribing Information. (n.d.). Genentech.
[4] FDA Approves Actemra (tocilizumab) for the Treatment of Hospitalized COVID-19 Patients. (n.d.). U.S. Food and Drug Administration.
[5] Pharmaceutical Market Research Reports. (n.d.). Various reports on autoimmune disease treatments. (General industry knowledge, no specific link applicable).
[6] Biosimilar Development and Regulatory Filings. (n.d.). Industry news and regulatory agency websites. (General industry knowledge, no specific link applicable).